Fragment size and dynamics of EGFR-mutated tumor-derived DNA provide prognostic information regarding EGFR-TKI efficacy in patients with EGFR-mutated NSCLC
Kei Kunimasa(Kobe University), Fumio Imamura(Osaka International Cancer Institute)
Cited by 0
Related Papers
Glucose metabolism‐targeted therapy and withaferin A are effective for epidermal growth factor receptor tyrosine kinase inhibitor‐induced drug‐tolerant persisters
|Cancer Science|2017|37
Early responses of <i>EGFR</i> circulating tumor DNA to EGFR tyrosine kinase inhibitors in lung cancer treatment
|Oncotarget|2016|22
Numerical indices based on circulating tumor DNA for the evaluation of therapeutic response and disease progression in lung cancer patients
|Scientific Reports|2016|17
Transient appearance of circulating tumor DNA associated with de novo treatment
|Scientific Reports|2016|13